The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients

E-ISSN： 1873-4316|12|11|1961-1973

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.12, Iss.11, 2011-11, pp. : 1961-1973

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System

Current Medicinal Chemistry, Vol. 15, Iss. 12, 2008-05 ,pp. : 1175-1191

Bentham Science Publishers

Access to resources Recommend Favorite

Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 4, 2009-04 ,pp. : 498-509

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Protein Kinase C-alpha (PKC-) in Cancer and its Modulation by the Novel PKC--Specific Inhibitor Aprinocarsen

Current Pharmaceutical Design, Vol. 10, Iss. 16, 2004-06 ,pp. : 1923-1936

Bentham Science Publishers

Access to resources Recommend Favorite

Fine Tuning of Protein Kinase C (PKC) Isoforms in Cancer: Shortening the Distance from the Laboratory to the Bedside

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 3, 2011-03 ,pp. : 185-199

Bentham Science Publishers

Access to resources Recommend Favorite

Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives

Current Cancer Drug Targets, Vol. 11, Iss. 2, 2011-02 ,pp. : 131-134

Bentham Science Publishers

Access to resources Recommend Favorite